Detection of Extended Spectrum β Lactamase and Amp C β Lactamase Resistance in the Gram Negative Bacterial Isolates of Ventilator Associated Pneumonia

David Agatha and B. Subitha*

Department of Microbiology, Thanjavur Medical College, Thanjavur, India

*Corresponding author

ABSTRACT

Ventilator-associated pneumonia (VAP) is an important nosocomial infection in mechanically ventilated patients at intensive care unit (ICU). The administration of accurate and timely initial empirical antibiotic therapy is essential to reduce the morbidity and mortality from Ventilator-associated pneumonia. Initial empiric antimicrobial therapy for VAP greatly depends on the type of causative pathogen and its resistance pattern. During the six months study period, 196 patients received mechanical ventilation. Endotracheal aspirates were collected from 22 mechanically ventilated patients with suspected ventilator associated pneumonia. 19 organisms were isolated. All Cefoxitin resistant isolates were studied for the presence of plasmid mediated AmpC beta-lactamase enzyme by Inhibitor disk based method and inducible AmpC beta-lactamase production by Ceftazidime-imipenem antagonism test (CIAT). ESBL production in the gram negative isolates was detected by Phenotypic Confirmatory Test. Incidence rate of VAP was 9.7%. Klebsiella pneumoniae (26%) was the most common organism followed by Pseudomonas aeruginosa (21%) and Acinetobacter spp (16%). (53%) of Gram negative isolates were positive for ESBL production. (6%) was positive for plasmid mediated Amp C beta lactamase production and (6%) was positive for inducible Amp C beta lactamase production. Due to the increasing incidence of drug-resistant organisms, VAP requires an early diagnosis and appropriate antibiotic treatment, to prevent mortality and morbidity. Hence, knowing the bacterial isolates and their antibiotic resistance pattern is essential to improve the clinical outcome of VAP.

Keywords: β Lactamase, Gram negative bacteria, Ventilator, Pneumonia

Article Info

Accepted: 10 January 2019
Available Online: 10 February 2019

Introduction

Ventilator associated pneumonia is the most common nosocomial infection in patients receiving mechanical ventilation. It occurs in 9-27% of mechanically ventilated patients (Arindam Dey et al., 2007, Gupta et al., 2011). Ventilator associated pneumonia (VAP) is a hospital acquired pneumonia that occurs 48 hours or more after tracheal intubation. It is classified as early onset or late onset pneumonia (Hanan H et al., 2014, Xiaofang Cai et al., 2011). Early onset pneumonia occurs within four days of intubation and late onset pneumonia develops after five days. In general, early VAP is caused by pathogens that are sensitive to antibiotics, whereas late onset VAP is caused by drug resistant
pathogens such as various beta-lactamas (AmpC β lactamase (AmpC), extended spectrum β-lactamas (ESBL) and metallo-β-lactamas (MBL) producing gram negative isolates and methicillin-resistant Staphylococcus. aureus (MRSA) (Marcos et al., 2013, Ramakrishna et al., 2012).

The most common mechanism of resistance in Gram negative bacteria is by the production of β lactamas which inactivate β lactam antibiotics. Among the β lactamas, Extended Spectrum β lactamas (ESBL) and Amp C β-lactamas are most commonly produced. Organisms producing ESBL are resistant to all penicillins, first, second and third generation cephalosporins and monobactam, however remain sensitive to carbapenems and cephamycins. AmpC beta-lactamas have broad substrate specificity and are classified as class C according to Ambler and group 1 by Bush-Jacoby-Medeiros. These enzymes are both chromosomal and plasmid mediated and confers resistance to narrow, broad spectrum cephalosporins, and β lactam β lactamase inhibitor combinations (Varsha Gupta et al., 2007; Gupta et al., 2013)

Initial empiric antimicrobial therapy for VAP greatly depends on the type of causative pathogen and its resistance pattern. Increasing drug resistance rates among the pathogens that frequently cause VAP may compromise treatment and result in prolongation of hospital stay and increase in mortality. There is a wide geographic and temporal variability of antibiotic resistance among the bacterial isolates of VAP (Chittawatanarat et al., 2014, Jean-Louis Trouillet et al., 1998). Hence this prospective study was conducted to evaluate the bacteriological profile, antibiotic resistance pattern, ESBL and AmpC β lactamase (AmpC) production in gram negative isolates of ventilator associated pneumonia.

Materials and Methods

This prospective study was conducted in a Tertiary care hospital over a period of 6 months. In that period 196 ventilated patients were observed. Endotracheal aspirates were collected from the patients on mechanical ventilation for more than 48 hours with new or progressive infiltrates, consolidation or cavitation on chest X-ray and one of the following: (a) New onset purulent bronchial secretions with leukopenia (white blood cell <1500/mm3) or leukocytosis (≥12,000/mm3), or core temperature ≥38.5 or ≤36°C without other cause.

The endotracheal aspirates were sent to the lab and processed immediately. The samples were first subjected to Gram’s staining and then quantitative cultures were performed.

Samples were mechanically liquefied and homogenized by vortexing for 1 min. Then 0.01 mL of sample solution was inoculated on sheep blood agar, chocolate agar (CA), and MacConkey agar by using 4 mm Nichrome wire loop. All plates were incubated overnight at 37°C and CA plates at 37°C in candle jar. All plates were checked for growth after 24 and 48 hrs of incubation. A detailed biochemical tests were performed to identify the significant growth of organism, and antibiotic sensitivity testing were performed on Mueller–Hinton agar plates by Kirby-Bauer disc diffision method. Zone diameter was measured and interpreted as per the Clinical and Laboratory Standards Institute (CLSI) guidelines.

Gram negative isolates resistant to 3rd Generation Cephalosporins were tested for ESBL production.

Phenotypic detection of ESBL production in the gram negative isolates by Phenotypic Confirmatory Test.
Ceftazidime (30 μg) disk and a Ceftazidime plus Clavulanic acid (Ca 30 μg + Caz 10 μg) disks were placed at a distance of 20 mm apart on a lawn of culture of the suspected ESBL producing clinical isolates on MHA.

The plates were incubated at 37°C overnight. The test organism was considered to produce ESBL if the zone size around the Ceftazidime plus Clavulanic acid disk increased >5 mm in comparison to the third generation Ceftazidime disk alone.

All Cefoxitin resistant Gram negative isolates were tested for AmpC beta-lactamase enzyme production.

Detection of plasmid mediated AmpC beta-lactamase production by Inhibitor disk based method.

The test culture was swabbed on Mueller-Hinton agar plates. Cefoxitin (30 μg) disk and Cefoxitin /BoronicAcid (BA) disk were placed at a distance of 20 mm from center to center.

An increase of >.5 mm around Cefoxitin /BA compared to Cefoxitin alone was considered positive for the presence of AmpC production (Philip et al., 2005).

Detection of inducible AmpC beta-lactamase production by Ceftazidime-imipenem antagonism test (CIAT)

The test culture was swabbed on Mueller-Hinton agar plates. Imipenem disk (10 μg) and Cefoxitin disk were placed 20 mm apart (edge-to-edge) from a Ceftazidime disk (30 μg. Antagonism was indicated by a visible reduction in the inhibition zone around the Ceftazidime disk adjacent to the Imipenem or Cefoxitin disks. This was regarded as positive for inducible AmpC beta-lactamase production (Vlademir et al., 2007).

**Results and Discussion**

During the study period, a total of 196 patients were on mechanical ventilation at Intensive Medical Care Unit, Neonatal Intensive Care Unit and Pediatric Intensive Care Unit in a Tertiary care Hospital. Endotracheal aspirates were collected from 22 mechanically ventilated patients with suspected ventilator associated pneumonia. 19 organisms were isolated and 3 Endo tracheal aspirates were reported as no growth. Incidence rate was 9.7%. *Klebsiella pneumoniae* (26%) was the most common organism followed by *Pseudomonas aeruginosa* (21%), *Acinetobacter* spp (16%), *Staphylococcus aureus* (16%), *Klebsiella oxytoca* (11%), *Citrobacter* spp (5%) and *Streptococcus* sp (5%).

The antibiotic susceptibility testing for Gram positive organisms revealed 100% sensitivity to Vancomycin and all the three *Staphylococcus aureus* isolates were resistant to cefoxitin (Fig. 1 and 2).

Gram negative organisms except *Klebsiella pneumoniae* and *Acinetobacter* spp were 100% sensitive to Imipenem.

Gram negative isolates (n=11) resistant to 3rd Generation Cephalosporins were tested for ESBL production. 4 *Klebsiella pneumoniae* isolates, 2 *Klebsiella oxytoca* isolates, 1 *Acinetobacter* spp isolate and 1 *Pseudomonas aeuriginosa* were positive for ESBL production

Two *Klebsiella pneumoniae*, two *Acinetobacter* spp one *Pseudomonas aeruginosa* resistant to Cefoxitin were tested for Amp C β lactamase production. One *Acinetobacter* spp was positive for plasmid mediated Amp C beta lactamase production. One *Pseudomonas aeruginosa* was positive for inducible Amp C beta lactamase production.
production. Out of 15 gram negative isolates, 8 (53%) were positive for ESBL production, 1 (6%) was positive for plasmid mediated Amp C beta lactamase production and 1 (6%) was positive for inducible Amp C beta lactamase production (Table 1).

**Table 1** Antibiotic sensitivity pattern of Gram negative organisms isolated from ventilator associated pneumonia

<table>
<thead>
<tr>
<th>Drugs</th>
<th><em>Klebsiella pneumoniae</em></th>
<th><em>Klebsiella oxytoca</em></th>
<th><em>Pseudo monas aeruginosa</em></th>
<th><em>Acinetobacter spp</em></th>
<th><em>Citrobacter spp</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin</td>
<td>80</td>
<td>50</td>
<td>50</td>
<td>67</td>
<td>100</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>40</td>
<td>50</td>
<td>50</td>
<td>33</td>
<td>100</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>20</td>
<td>0</td>
<td>75</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Ceftazidine</td>
<td>20</td>
<td>0</td>
<td>50</td>
<td>33</td>
<td>100</td>
</tr>
<tr>
<td>Piperazilin tazobactum</td>
<td>80</td>
<td>100</td>
<td>75</td>
<td>33</td>
<td>100</td>
</tr>
<tr>
<td>Imipenem</td>
<td>80</td>
<td>100</td>
<td>100</td>
<td>33</td>
<td>100</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>60</td>
<td>100</td>
<td>75</td>
<td>33</td>
<td>100</td>
</tr>
</tbody>
</table>

**Chart I: Pathogen isolated from Ventilator Associated Pneumonia**

**Fig. 1** Inducible Amp C beta lactamase detection by Ceftazidime-imipenem antagonism test
VAP requires a rapid diagnosis and initiation of appropriate antibiotic treatment, to prevent mortality and morbidity. Inappropriate and inadequate antibiotic treatment causes emergence of drug resistance in pathogens and poor prognosis in patients (Steven et al., 2006, Ali Amanati et al., 2017, Su Young Chi et al., 2012).

The incidence of VAP in our study was 9.7%, which was lower than studies done by Alok Gupta et al., (28.04%), SarojGolia et al., (35.78%), Gadani et al., (37%) and Dey et al., (45.4%) Rajashekar et al., reported a very high incidence rate of 73%. The lower incidence rate may be due to death of most of the patients on the day of mechanical ventilation itself.

Out of 19 VAP cases, 43% were categorized under early-onset VAP and 57% under late-onset VAP which was in concordance with study conducted by Dey et al., Klebsiella pneumoniae and Pseudomonas aeruginosa were the commonest isolates obtained in both early and late onset VAP cases, which were also reported as the commonest isolates by study conducted by Ramakrishna et al., (2012).

In our study 53 % of Gram negative isolates were ESBL producers. Saroj Golia et al., and Dey et al., also observed a high prevalence of ESBL producers in their study. Chromosomal Amp C β Lactamase resistance was seen in 6% of our isolates and plasmid mediated Amp C beta lactamase production was seen in (6%) which was similar to Gupta et al., observation (11%). Cefoxitin resistance in non-Amp C producing Klebsiella pneumoniae is often due to porin deficient mutants. The interruption of a porin gene by insertion sequences is a common type of mutation that causes the loss of porin expression and increased Cefoxitin resistance in Klebsiella pneumoniae.

Our results suggest no difference in the rate of drug resistant pathogens between early-onset and late-onset VAP. Many studies have shown a higher association between resistant pathogens and late-onset VAP. This association is due to previous antibiotic therapy, time on mechanical ventilation, and local factors, which are institution specific. Ibrahim and colleagues have reported resistant pathogens to be common in both early-onset and late-onset. The overall picture suggests that number of drug-resistant strains of various organisms is rising and is an important cause of VAP in our setting.

In conclusion, this study suggests that most cases of VAP in our setting are caused by highly resistant strains. Local epidemiological
data like this should be collected at all centers, as such information can help in guiding the initial empirical antibiotic therapy, which would be more rationale and help in decreasing mortality and morbidity. This would also help in preventing development of more resistant strains.

References


Marcos I Restrepo, MD MSc, Janet Peterson, Comparison of the Bacterial Etiology of Early-Onset and Late-Onset Ventilator-Associated Pneumonia in Subjects Enrolled in 2 Large Clinical Studies. Respir Care. 2013 Jul; 58(7): 1220–1225.


Ramakrishna PaiJakribettu and Rekha Boloor, Characterisation of aerobic bacteria isolated from endotracheal aspirate in adult patients suspected ventilator associated pneumonia in a tertiary care center in Mangalore. Saudi J Anaesth. 2012 Apr-Jun; 6(2): 115–119.,

Saroj Golia,1 Sangeeth, K.T. Microbial Profile of Early and Late Onset Ventilator Associated Pneumonia in The Intensive Care Unit of A Tertiary Care Hospital in Bangalore, India J Clin Diagn Res. 2013 Nov; 7(11): 2462–2466.


Su Young Chi, M.D., Tae Ok Kim, M.D., Chan Woo Park, M.D., Jin Yeong Yu, M.D., Boram Lee, M.D., Ho Sung Lee, M.D., Yu Il Kim, M.D., Sung Chul Lim, M.D., Bacterial Pathogens


How to cite this article:

doi: https://doi.org/10.20546/ijcmas.2019.802.132